Status:
COMPLETED
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
Lead Sponsor:
Pfizer
Conditions:
Overactive Bladder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This extension trial of SP668 consists of two phases: double-blind treatment and open-label extension. The trial provides subjects the option of long-term treatment with sustained release (SR) fesoter...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Overactive bladder
Exclusion
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00220389
Start Date
June 1 2003
End Date
June 1 2007
Last Update
October 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
RTP, North Carolina, United States